Last reviewed · How we verify
Asbjørn Mohr Drewes — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Opium tincture | Opium tincture | marketed | Opioid analgesic | Mu opioid receptor (primary); delta and kappa opioid receptors (secondary) | Pain management; Gastroenterology |
Therapeutic area mix
- Pain management; Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Ajay Wasan, MD, Msc · 1 shared drug class
- Alza Corporation, DE, USA · 1 shared drug class
- Archimedes Development Ltd · 1 shared drug class
- BioDelivery Sciences International · 1 shared drug class
- Boston Children's Hospital · 1 shared drug class
- Brigham and Women's Hospital · 1 shared drug class
- AdventHealth · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Asbjørn Mohr Drewes:
- Asbjørn Mohr Drewes pipeline updates — RSS
- Asbjørn Mohr Drewes pipeline updates — Atom
- Asbjørn Mohr Drewes pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Asbjørn Mohr Drewes — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/asbj-rn-mohr-drewes. Accessed 2026-05-16.